A Design of Experiment approach to predict product and process parameters for a spray dried influenza vaccine  by Kanojia, Gaurav et al.
International Journal of Pharmaceutics 511 (2016) 1098–1111A Design of Experiment approach to predict product and process
parameters for a spray dried inﬂuenza vaccine
Gaurav Kanojiaa,b,1, Geert-Jan Willemsa, Henderik W. Frijlinkb, Gideon F.A. Kerstena,c,
Peter C. Soemaa,*,2, Jean-Pierre Amorija,2,3
a Intravacc (Institute for Translational Vaccinology), Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands
bUniversity of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
cDivision of Drug Delivery Technology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
A R T I C L E I N F O
Article history:
Received 4 May 2016
Received in revised form 28 July 2016
Accepted 10 August 2016
Available online 12 August 2016
Keywords:
Spray drying
Process optimization
Process parameters
Quality by design
Nozzle gas ﬂow rate
A B S T R A C T
Spray dried vaccine formulations might be an alternative to traditional lyophilized vaccines. Compared to
lyophilization, spray drying is a fast and cheap process extensively used for drying biologicals. The
current study provides an approach that utilizes Design of Experiments for spray drying process to
stabilize whole inactivated inﬂuenza virus (WIV) vaccine. The approach included systematically
screening and optimizing the spray drying process variables, determining the desired process parameters
and predicting product quality parameters. The process parameters inlet air temperature, nozzle gas ﬂow
rate and feed ﬂow rate and their effect on WIV vaccine powder characteristics such as particle size,
residual moisture content (RMC) and powder yield were investigated. Vaccine powders with a broad
range of physical characteristics (RMC 1.2–4.9%, particle size 2.4–8.5 mm and powder yield 42–82%) were
obtained. WIV showed no signiﬁcant loss in antigenicity as revealed by hemagglutination test.
Furthermore, descriptive models generated by DoE software could be used to determine and select (set)
spray drying process parameter. This was used to generate a dried WIV powder with predeﬁned
(predicted) characteristics. Moreover, the spray dried vaccine powders retained their antigenic stability
even after storage for 3 months at 60 C. The approach used here enabled the generation of a
thermostable, antigenic WIV vaccine powder with desired physical characteristics that could be
potentially used for pulmonary administration.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Many existing vaccines are currently distributed and adminis-
tered in a liquid form. Liquid vaccines need to be stored at 2–8 C to
remain stable. This dependency on a steady cold chain makes
vaccine distribution complex and expensive, especially in devel-
oping countries (Wang, 1999). Dried vaccines can overcome this
requirement for a cold chain, as they possess a longer shelf life at
elevated temperatures (Geeraedts et al., 2010; Smith et al., 2015).Abbreviations: QbD, quality by design; DoE, Design of Experiments; QTTP,
quality target product proﬁle; WIV, whole inactivated inﬂuenza virus; XRD, X-ray
diffractometry; DSC, differential scanning calorimetry; RMC, residual moisture
content.
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0378-5173/ã 2016 The Authors. Published by Elsevier B.V. This is an open access articlMoreover, dry powder vaccine formulations have the potential to
be used for alternative vaccine delivery routes, such as the
intranasal, pulmonary or oral routes (Dicko et al., 2000; Giudice
and Campbell, 2006; Tonnis et al., 2012; Amorij et al., 2010).
An established method to produce dried biologics is spray
drying. Spray drying has the advantage over traditional drying
techniques (such as freeze-drying) that it is relatively fast and has
lower operating costs. Moreover, it results in a dispersible ﬁne
powder compared to a dry cake as obtained by freeze-drying,
which may enable further powder handling and usage for
alternative delivery routes.
Powders with different physiochemical and morphological
properties can be obtained by spray drying. The powder properties
depend on the applied process parameters and composition of the
liquid feed (Crowe et al., 1994; Jain and Roy, 2008). The spray
drying process consists of nebulization of a liquid product,
generating aerosols, into a heated gaseous drying medium,
resulting in a dry powder (Fig. 1). The large surface area of the
aerosols results in a relative rapid drying process. Depending one under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig.1. Spray drying process: A liquid inﬂuenza vaccine (whole inactivated inﬂuenza virus vaccine) was spray dried with trehalose as an excipient to produce a powder vaccine.
Investigated process parameters are indicated in red. Aspirator capacity was kept ﬁxed at 22 m3n/h (highest aspirator setting possible).
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between 0.2–30 s (Anon., 1999). During drying, the protein in
evaporating droplets may experience reversible or irreversible
denaturation. This could be due to the loss or weakening of
hydrogen bonds and simultaneous increase in hydrophobic
interactions during evaporation of water. However, the self-cooling
effect of droplets due to water evaporation prevents the tempera-
ture increase of the droplet surface above the wet bulb
temperature (temperature of drying aerosols achieved through
evaporation cooling) (Katja, 2011). Thus, spray drying may be an
appropriate procedure for drying thermolabile vaccines and has
been used to produce experimental dry powder vaccines against
measles (Lin et al., 2011; Ohtake et al., 2010), inﬂuenza (Lovalenti
et al., 2016; Saluja et al., 2010; Scherliess et al., 2014; Sou et al.,
2015), tuberculosis (Wong et al., 2007) and hepatitis B (Chen et al.,
2010). Moreover, dry powdered measles vaccine has showed
promising results in phase 1 clinical trials (MVDP author group
et al., 2014). Therefore, spray drying might be a suitable alternative
method to obtain dry powders of a variety of vaccines (Amorij et al.,
2008).
The spray-drying process used to produce these powders with
desired product characteristics is usually optimized by a one-
factor-at-a-time (OFAT) approach, where the effect of process
parameters on the product are assessed in a linear fashion, one-at-
a-time. This consumes a lot of time and resources. Moreover, itrequires a large number of experiments and interactions between
parameters are frequently missed. A Design of Experiments (DoE)
approach can be used instead in order to systematically screen and
optimize processes. DoE is a structured approach that can be used
to identify critical and non-critical parameters, and their respective
interactions, of a production process. Moreover, it can be used to
quantify the impact of raw materials and process parameters on
the product characteristics and quality (Cook et al., 2013). Several
studies have employed a DoE approach to investigate and optimize
the spray drying process of proteins (Prinn et al., 2002; Maltesen
et al., 2008) and liposomal adjuvants (Ingvarsson et al., 2013).
However, the potential of utilizing DoE for producing spray-dried
powder vaccines has not been explored so far.
To maintain the structural integrity during and after the drying
process, biological products such as proteins or vaccines often
require excipients that act as stabilizers in their formulation. The
sugar trehalose is an excipient commonly used for stabilizing
vaccines, due to its good protein-stabilizing characteristics
(Geeraedts et al., 2010; Ogain et al., 2011). Including trehalose in
the vaccine formulations for spray drying might therefore be
essential to obtain a stable vaccine product after spray drying.
Previously, spray drying of inﬂuenza vaccines has been described
using various sugars, Maa et al. (Maa et al., 2004) were ﬁrst to
describe the use of trehalose, Sou et al. (2015) combined trehalose
with leucine, whereas Scherliess et al. (2014) showed the
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Saluja et al. (2010) described the use of the spray drying process
with inulin as stabilizer.
The goal of this study was to investigate the use of a DoE
approach to systematically screen and optimize the spray drying
process parameters (inlet air temperature, nozzle gas ﬂow rate,
and feed ﬂow rate) and predicting the process settings needed to
achieve the targeted product quality parameters like outlet
temperature, particle size, powder yield and residual moisture
content. As a model antigen, whole-inactivated inﬂuenza virus
(WIV) vaccine was used, with trehalose as a stabilizing excipient.
Using DoE software, an experimental design was generated to
assess the impact of various process parameters (inlet air
temperature, nozzle gas ﬂow rate, and feed ﬂow rate) and
trehalose concentrations on the ﬁnal product characteristics
(particle size, powder yield and residual moisture content).
Regression models were ﬁtted on the measured output param-
eters, and the prediction power of the model was assessed by
selecting three untested combinations of process parameters
within the investigated design space. Finally, the antigenic
recovery and thermostability of the obtained spray-dried vaccines
was assessed.
2. Materials and methods
2.1. Inﬂuenza vaccine
Inﬂuenza A/PR8/34 WIV was obtained by inactivating egg-
propagated inﬂuenza virus with b-propiolactone as described
previously (Hendriks et al., 2011). The bulk vaccine was
concentrated with Centriprep centrifugal ﬁlters (Millipore) with
a molecular weight cut-off (MWCO) of 10 kDa, formulated in HBS
(20 mM HEPES, 125 mM NaCl, 9 mM CaCl2, 5 mM MgCl2). The ﬁnal
WIV stock contained 800 mg/mL HA that was determined by
surface plasmon resonance as described previously (Hendriks
et al., 2011). The vaccine solution to be spray dried was prepared by
mixing the WIV stock with D-(+)-trehalose dihydrate (Sigma-
Aldrich) solution in PBS (resulting in weight ratio hemagglutinin
protein (HA)/trehalose: 1/400). The ratio of protein to sugar was
chosen based on previous research experience with spray-freeze
drying of inﬂuenza vaccines (Geeraedts et al., 2010). The trehalose
solution was ﬁltered using a 0.45 mm Millex-HV ﬁlter (Millipore)
prior to mixing with WIV.
2.2. Spray drying of inﬂuenza vaccine formulation
WIV powders were produced using a Büchi mini spray-drier B-
290 in conjunction with a high performance cyclone and a B-296
dehumidiﬁer (both from Büchi Labortechnik AG). All the experi-
ments were performed in a closed loop conﬁguration using
nitrogen as drying medium.Table 1
Quality targeted product proﬁle. Describes the desired quality target proﬁle for a dry p
Desired
response
Target Rationale
Particle size 1–5 mm Particle size that is su
Residual
moisture
content
3% or less Within the prescribed
1990)
Powder Yield 70% or more Powder yield should b
Stability Less than 10% loss in HA titers during
storage for 12 months at 2–8 C
Powder vaccine should
inﬂuenza vaccines (Far
calculated theoreticallNitrogen being inert in nature was preferred to avert any
unwanted reaction that might occur in the presence of air as drying
medium. A two-way nozzle with oriﬁce diameter of 0.7 mm was
used in a co-current mode with nitrogen as atomizing gas. The
nitrogen pressure was set constant at 5 bar. The spray drying
parameters were varied in accordance with the experimental
design matrix (Table 2). The feed ﬂow rate is displayed in
percentage (%) on the equipment and feed ﬂow rate of 5, 10 or 15%
corresponding to experimentally determined ﬂow rates ranged
from 1.0, 3.4 and 4.5 mL/min, respectively. An atomizing airﬂow of
7.3  17.5 L/min corresponds to a setting from 30 to 50 mm (normal
liter [Ln] is the volume at 0 C and 1 atm). The aspirator rates were
set at 22 m3n/h in all experiments; this corresponded to instrument
setting of 100%.
After spray drying the spray dried product was collected and,
aliquoted (100 mg) in vials (3 mL vial, Nuova Ompi) in a glove box
under a relative humidity of <3% (Terra Universal Inc, Series 100)
and sealed. The yield was deﬁned as the ratio between the amount
of powder obtained and the amount of substance introduced in the
liquid feed (Eq. (1)) (Maltesen et al., 2008). The weight of buffer
salts was not included in yield calculation as they were constant for
all formulations.
Powder Yield %½  ¼ Collected powder weight g½ 
Trehalose in the feed g½   100 ð1Þ
2.3. Target product proﬁle
The quality target product proﬁle (QTTP) was deﬁned, and
process parameters that may have an impact on residual moisture
content (RMC), particle size, powder recovery and outlet temper-
ature were determined from previous studies on spray drying
(Prinn et al., 2002; Ingvarsson et al., 2013; Ogain et al., 2011). The
QTPP describes the characteristics of the ﬁnal product (Table 1).
The parameters investigated were inlet temperature, atomization
airﬂow rate (nozzle pressure), feed ﬂow rate and feed excipient
concentration. Additional factors such as raw materials and
operator were kept constant. The investigated space would result
in a design space where one or more of the targeted product proﬁle
could be achieved.
2.4. Design of Experiments (DoE)
The DoE model was prepared and evaluated using MODDE 10.0
(Umetrics AB). Models were ﬁtted with multiple linear regression
(MLR) and adjusted by removing non-signiﬁcant model terms.
Prior to our study, screening experiments were performed using a
full factorial design to determine the most relevant input process
parameters that affected the output process and product
parameters. Since the weight ratio of HA/trehalose was 1/400, it
was decided to ﬁnd the appropriate process input parameter
ranges without using the antigen. Thereby, assuming that such lowowder Whole inactivated inﬂuenza virus vaccine.
itable for inhalational and parenteral administration after reconstitution.
 limits for dried biologicals (May et al., 1992; The Food and Drug Administration,
e sufﬁcient to make the process economically feasible.
 be at least as stable as the described stability for whole inactivated liquid
nsworth et al., 2011; Kumru et al., 2014). The human dose 15 mg of HA can be
y based on powder yield of the vaccine.
Table 2
Experimental design matrix. The design matrix shows the input parameters set for spray drying (inlet temperature, nozzle gas ﬂow rate, feed ﬂow rate, trehalose
concentration) and the output parameters that were experimentally determined [Particle size(X50 median particle size) and span, outlet temperature, RMC and powder
yield]. Aspirator was set at maximum instrument setting.
Exp
No.
Inlet temp
(C)
Nozzle gas ﬂow rate
(L/min)
Feed ﬂow rate
(mL/min)
Trehalose conc
(mg/mL)
Particle size
[X50] (mm)
Size (span)
(X90 X10)/X50
Outlet
temp (C)
Moisture
content (%)
Powder Yield
(%)
1 110 7.3 1.0 100 6.1 1.7 67 4.2 63
2 160 7.3 1.0 100 6.9 2.0 91 1.4 72
3 110 17.5 1.0 100 2.4 2.1 58 2.4 82
4 160 7.3 4.5 100 7.3 2.0 78 3.8 53
5 110 17.5 4.5 100 5.7 2.0 48 7.7 64
6 160 17.5 4.5 100 3.2 1.5 63 3.1 72
7 110 7.3 1.0 150 6.8 1.3 63 4.1 61
8 110 17.5 1.0 150 2.9 1.6 61 2.6 75
9 160 17.5 1.0 150 2.9 1.2 83 1.9 69
10 110 7.3 4.5 150 8.5 1.8 53 2.9 42
11 160 7.3 4.5 150 7.9 1.8 76 3.6 52
12 160 17.5 4.5 150 3.1 1.5 73 2.3 69
13 110 12.4 3.4 125 4.5 1.8 55 3.7 69
14 160 12.4 3.4 125 4.3 2.0 78 2.4 70
15 135 7.3 3.4 125 7.5 1.9 68 4.9 57
16 135 17.5 3.4 125 3.3 2.1 65 3.1 76
17 135 12.4 1.0 125 3.7 1.8 74 2.4 77
18 135 12.4 4.5 125 4.2 1.6 61 3.3 69
19 135 12.4 3.4 100 3.8 2.1 67 2.9 78
20 135 12.4 3.4 150 4.2 2.1 62 2.8 62
21 135 12.4 3.4 125 4.1 1.6 63 3.1 67
22 135 12.4 3.4 125 4.5 2.0 66 3.2 72
23 135 12.4 3.4 125 4.4 2.1 66 3.5 73
G. Kanojia et al. / International Journal of Pharmaceutics 511 (2016) 1098–1111 1101antigen weight ratio would not signiﬁcantly inﬂuence the output
parameters. The model was further optimized using a Central
Composite Family (CCF) design, including WIV as the model
antigen. A reduced CCF design was used for optimization,
consisting of in total 23 experimental runs. The choice of a
reduced CCF design was made due to fewer experimental runs
giving the same amount of information as the CCF. To reduce
systematic errors, all the experiments were completely random-
ized.
2.5. Antigen characterization
2.5.1. WIV hemagglutination titer
To determine the hemagglutination titer of the WIV in dried
vaccine powder, a hemagglutination assay was performed as
described previously by Soema et al. (2014). Spray-dried vaccines
were reconstituted accordingly in puriﬁed water (MilliQ) corre-
sponding to a HA concentration of 0.1 mg/mL. Finally, PBS was
added to the reconstituted vaccine to obtain a 1:10 dilution.
Diluted vaccine solution were transferred to a 96-wells V-bottom
plate (Greiner) and serially diluted two-fold with PBS. All the wells
consisted of 50 mL after dilution. Next, an equal volume of a 1%
suspension of turkey erythrocytes (Harlan laboratories) was added
to the wells and the plates were incubated for 1 h at room
temperature. The titer was determined by visual observation of
agglutination of RBC in the wells and subsequently expressed as
the reciprocal of the highest dilution that yielded complete
hemagglutination. The titers were determined on reconstituted
powders just after spray drying (t = 0) and were repeated on stored
vaccine powder over a period of 3 months at intervals of one
month. HA titers (activity) of the samples at each condition were
calculated relative to the starting liquid mixture of WIV with
excipient at 4 C. The Log2 HA titers were expressed in percentage
for comparison between different samples.
2.5.2. Dynamic light scattering (DLS)
The size of WIV after reconstitution was measured using a
Zetasizer Nano-ZS system (Malvern Instruments). DLSmeasurements were done in triplicate with 0.2 mL of the
reconstituted WIV samples. Samples were prepared with vaccine
powder reconstituted by gentle shaking in puriﬁed water (MiliQ)
(HA 0.1 mg/mL) at an operating temperature of 25 C. Homogeneity
of the size distribution was reﬂected in the polydispersity index
(PdI).
2.6. Residual moisture content (RMC)
The RMC of spray dried inﬂuenza vaccine samples was
determined using a C30 Compact Karl Fischer Coulometer
(Mettler-Toledo). Samples of approximately 100 mg of dried
powder vaccine in vials were reconstituted in 1 mL HYDRANAL
Coulomat A (Sigma-Aldrich) and subsequently injected into the
titration vessel. Each sample was measured in triplicate. The
relative and absolute moisture content were calculated from the
standard plot, based on the weight of the dried product in the vial,
volume of the reconstituted reagent, volume of extracted sample
injected into the titration vessel and the blank titration.
2.7. Physical characterization of the vaccine powders
2.7.1. Geometric particle size
The geometric particle size (X50 deﬁned as the median particle
size) of spray dried powder product was analyzed by laser
diffraction with a Helos system (Sympatec GmbH). The powder
was dispersed into the Helos system using an aspiros dispersing
system operated at a dispersing pressure of 1.0 bar. The vaccine
powder was measured with lens having a measuring range of 0.1/
0.18–35 mm. Furthermore, to check for any aggregates the dried
vaccine powder was measured again with a lens having a
measuring range of 4.5–875 mm. Moreover, increasing the disper-
sion pressure to 5 bar did not result in change of the measured
particle size distribution, which indicates that the size distribution
of the primary particles was obtained at 1 bar. Results are the mean
of three measurements. The span of the produced powders was
calculated using the equation: span = (X90 X10)/X50. The span is a
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distribution.
2.7.2. Differential scanning calorimetry
Modulated differential scanning calorimetry (mDSC) was
conducted using a TA DSC Q100 (TA instruments). Samples
weighing between 10.0–15.0 mg were crimped in hermetically
sealed pans for measurement. The glass transition temperature
(Tg) was determined by modulated DSC (MDSC); the samples were
cooled to 10 C and then heated to 180 C at a rate of 2.0 C/min. The
modulation amplitude was set at 0.318 C every 60 s. The
midpoint in deﬂection in the reverse heat ﬂow was taken as the Tg.
2.7.3. Scanning electron microscopy (SEM)
The morphology of the particles was visualized using a JSM
6301F scanning electron microscope (JEOL). Samples (Experiment
1, 7, 8, 11 and 12) were prepared by placing the powders on double-
sided sticky carbon tape on a metal disk. Subsequently, the
particles were coated with a gold layer of approximately 10 nm
using a Balzers 120 B sputtering device (Balzer UNION). The voltage
used for analysis was 10 kV with a spot size of 7–8. Images were
taken at a magniﬁcation of 1000 and 5000.
2.7.4. Powder X-ray diffractometry (XRD)
Vaccine powder samples (Experiment 1, 7, 8, 11 and 12) were
analyzed by an D2 Phaser desktop X-ray diffractometer equippedFig. 2. Powder morphology of spray dried WIV powders. Scanning electron micrographs
3.1 mm), Bottom: Run 8 (X50: 2.9 mm)]. Magniﬁcation images left (1000) and right (5with a LynxEye Si strip one-dimensional detector (both from
Bruker AXS). The samples were exposed to Cu Ka (X-rays) at an
angular ranging was from 5 to 60 2&z.Theta; with a step size of
0.01 and a dwell time of 0.5 s. The crystalline status of the powder
was assessed qualitatively by examination of the resulting
diffraction patterns. The upper limit of detection of crystallinity
is 2% of the total sample volume.
3. Results
A DoE approach was used to systematically investigate the
effects of feed ﬂow rate, inlet temperature, nozzle gas ﬂow rate
(nozzle pressure) and trehalose concentration (which were
established to be the important input process parameters in prior
screening studies) on the output parameters (outlet temperature)
and vaccine powder characteristics. To gain more insight in the
relation between input parameters on the responses, a reduced
CCF design was adopted for further optimization of process
parameters (Table 2). After spray drying and analyzing the
formulations of the CCF design, MLR models were ﬁtted for each
output parameter. Valid models were obtained for outlet
temperature, particle size, residual moisture content and powder
yield, described in model ﬁt (R2), prediction power (Q2),
reproducibility and a valid model. of representative spray dried trehalose-stabilized WIV vaccines [Top: Run 12 (X50:
000).
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3.1.1. Particle shape and size
All the experiments in the current design yielded white to off-
white powders after spray drying. No visible aggregates could be
observed in the powders by eye. SEM was performed on the
powders to provide particle form and surface morphology. The
powders showed a relatively homogenous surface morphology.
Typically, they were spherical with a smooth surface (Fig. 2). In
addition, the particle size of the acquired powder vaccines was
measured by laser diffraction. The powders had a median volume
diameter (X50) between 2.4 mm and 8.5 mm, with narrow size
distributions (Table 2). To investigate the relationship between the
input parameters and the particle size, a MLR model was ﬁtted on
the data (Fig. 3A). The model ﬁt and prediction power (R2 = 0.965,
Q2 = 0.917) were good, and model reproducibility and validity were
sufﬁcient. The regression coefﬁcient plot (Fig. 3B) shows that the
nozzle gas ﬂow rate (nozzle pressure), inlet air temperature and
feed ﬂow rate were relevant to particle size. The effect of the two
most inﬂuential factors, feed ﬂow rate and nozzle pressure, on the
particle size is shown in Fig. 3C. An increase in feed ﬂow rateFig. 3. Regression model for particle size. A: Summary of ﬁt plot for particle size. R2 (Good
than 0.5 is a good ﬁt) (Q2 = 0.917). Model validity (value greater than 0.25 indicates go
Regression coefﬁcients for particle size. C. Response contour plots for particle size. The
account and other factors were kept constant. The color regions represent the predicted re
instrument setting.resulted in bigger particles, whereas an increase in nozzle pressure
resulted in a decreased in particle size (summarized in Table 6).
3.1.2. Powder yield
The inﬂuence of spray drying process parameters on the yield of
the vaccine powder was assessed. The powder yields ranged from
42% to 82%, and approximately half of the runs in the design had a
yield of >70%, which was the targeted yield in the QTPP (Table 2).
Applying a MLR model resulted in a good model ﬁt, prediction
power, reproducibility and validity (Fig. 4A). Three input param-
eters (nozzle pressure, feed ﬂow rate and trehalose concentration)
were found to affect the yield (Fig. 4B). An increase in nozzle
pressure increased the powder yield, whereas increasing the feed
ﬂow rate and trehalose concentration decreased the powder yield.
The effect of two most inﬂuential factors nozzle pressure and feed
ﬂow rate on predicted powder yield is shown in contour plot,
Fig. 4C. In general, high nozzle pressure and lower feed ﬂow rate
with other parameters ﬁxed favors higher powder yield.
3.1.3. Residual moisture content
The moisture content of the produced powders was between
1.2% and 4.9% (Table 2). One outlier was detected (experiment Noness of ﬁt, 1 = perfect model) (R2 = 0.964). Q2 (Goodness of prediction, values greater
od ﬁt). Reproducibility (greater than 0.5 indicates a small experimental error) B:
 effect of the two most inﬂuential factors (as observed from Fig B) was taken into
sponse (particle size) for deﬁned parameter settings. Aspirator was set at maximum
Table 3
Thermostability of spray dried formulations. Spray dried formulations were stored up to 3 months at 60 C, and their antigenicity was subsequently determined by
hemagglutination (HA). Liquid WIV was also stored at 60 C as a control. The HA titers were measured in triplicate; since no difference in the triplicate of the titers was
observed no standard deviations are shown. Number 1–23 represent the different formulations spray dried according to the design described in Table 2.
Type Day 0 HA titers (%) Day 30 HA titers (%) Day 60 HA titers (%) Day 90 HA titers (%)
Liquid WIV stored at 60 C (negative control) D0 D1 D2 D3 D4 D5
100 72 56 45 34 0
Experiment 1 100 100 100 96
Experiment 2 100 104 106 96
Experiment 3 100 104 100 96
Experiment 4 94 104 104 96
Experiment 5 90 101 100 92
Experiment 6 86 105 104 102
Experiment 7 87 98 98 96
Experiment 8 100 108 105 96
Spray dried 9 93 105 112 102
Experiment 10 96 105 100 98
Experiment 11 93 108 115 105
Experiment 12 100 101 100 92
Experiment 13 100 105 105 102
Experiment 14 96 105 105 98
Experiment 15 96 107 100 98
Experiment 16 100 104 98 96
Experiment 17 100 104 104 96
Experiment 18 100 112 105 102
Experiment 19 100 108 98 96
Experiment 20 94 104 98 96
Experiment 21 87 95 98 96
Experiment 22 96 94 100 98
Experiment 23 100 102 105 102
Table 4
Prediction power of DoE model. Three experimental input parameters were chosen from the predicted design space (Fig. 9). Point A was selected for proof-of principle
purposes for a formulation that would result in targeted product speciﬁcations (within optimum area of predicted design space). Point B and C do not meet all criteria for
targeted product (outside optimum area of design space). The rationale for choosing B and C was to conﬁrm the prediction abilities of the model within the design space but
outside the optimum area. Aspirator was set at maximum instrument setting for the three experimental runs.
Exp No. Inlet temp (C) Nozzle gas ﬂow rate (L/min) Feed ﬂow rate (mL/min) Trehalose conc (mg/mL)
Within optimum area(A) 120 12.4 1.0 100
Outside optimum area (B) 135 10.5 1.0 125
Outside optimum area spot (C) 132 9.0 1.0 125
1104 G. Kanojia et al. / International Journal of Pharmaceutics 511 (2016) 1098–11115), which was subsequently excluded from the regression model.
Fitting a MLR regression model on the RMC data resulted in a good
model ﬁt, prediction power, model reproducibility and validity
(Fig. 5A). The resulting regression coefﬁcient plot shows that manyTable 5
Assessment/qualiﬁcation of the prediction models. The acquired model from experiment
outlet temperature and powder yield. Predictions are expressed as mean  95% conﬁdenc
size and RMC represent mean  SD of one sample measured in triplicate N = 3 (observe
Output parameters Predicted Predicted low
Particle size(mm)
A 3.38 3.00 
B 4.23 3.88 
C 5.88 5.55 
Residual moisture content (%)
A 2.1 1.8 
B 2.7 2.4 
C 3.6 3.3 
Outlet temperature (C)
A 67 65 
B 74 73 
C 75 73 
Powder yield (%)
A 80 76 
B 73 70 
C 66 63 process parameters inﬂuence the RMC of the spray-dried vaccine
powders (Fig. 5B). The effect of two most inﬂuential factors nozzle
pressure and inlet temperature on predicted RMC is shown in
contour plot, Fig. 5C. An increase in inlet temperature or nozzleal design described in Table 2 predicted the particle size, residual moisture content,
e intervals. The upper and lower ranges were taken from the model. Data for particle
d).
er range Predicted upper range Observed
3.77 3.08  0.1
4.57 4.07  0.1
6.21 5.78  0.1
2.5 2.4  0.03
3.0 2.7  0.02
4.0 2.8  0.02
69 67
76 76
77 75
84 77
77 73
69 64
Table 6
Summary of main ﬁndings. Description of the relationships between process input parameters and product output parameters in this study for the spray drying process
(Büchi, B-290 and 0.7 mm oriﬁce nozzle) of a whole inactivated inﬂuenza vaccine. Aspirator capacity was kept ﬁxed at 22 m3n/h [highest aspirator setting possible (of used
equipment)].
Parameter/
Dependence
Nozzlepressure " Inlet air temperature " Feed ﬂow rate " Trehalose concentration "
Particle
Size
### Greater energy for dispersion,
smaller particles after
atomization
# More evaporation after shell
formation
" More ﬂuid needs to be dispersed No effect in the investigated
range
Powder
Yield
" Smaller particles, improved
drying, lesser deposition in drying
chamber
"" Eventually dryer product but
chances of sticking at high
temperatures
# Higher water content to evaporate,
more sticking but dependent on other
variables
# Bigger droplets for drying,
more deposition in drying
chamber
Residual
moisture
content
# Smaller droplets thus better
drying
## Lower relative humidity in air "" More water for evaporation leads to
higher partial pressure
# Less water evaporated, lower
partial pressure
Outlet
Temperature
# More nitrogen inﬂow in system
for heating.
""" Directly proportional
as available energy for drying increases
proportionally with rise in inlet
temperature
## More water needs to be evaporated " Less water needs to be
evaporated as more excipient in
the droplet
Antigenicity No effect in the investigated range No effect in the investigated range No effect in the investigated range No effect in the investigated
range
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ﬂow rate increased the RMC of the powders.
3.1.4. Amorphous nature of dried powder vaccine
We had observed some samples with high RMC and since water
is a potent plasticizer for sugar glasses. We wanted to conﬁrm the
amorphousness of the samples. The amorphous nature of the spray
dried vaccine powders was determined by assessing the glass
transition temperatures (Tg) with DSC and crystallinity by X-ray
diffraction (XRD). Tg analysis of the vaccine powders gave values
between 45 C and 83 C for the highest and lowest RMC-
containing powders, respectively (Supplementary Table 2). The
X-ray diffraction (XRD) proﬁles of the excipient (trehalose
dihydrate) and spray dried inﬂuenza vaccines are shown in
Fig. 6. The proﬁles indicate that solid trehalose dihydrate was
crystalline prior to spray drying, as peaks were observed. On the
other hand, no peaks were detected in the spray dried vaccine
powders, indicating that the powders were amorphous.
3.2. Outlet temperature
The outlet air temperature was determined during the spray
drying process of each experiment in the design. During spray
drying of the inﬂuenza vaccine formulations the outlet tempera-
ture was found to be between 48 C and 91 C (Table 2). A MLR
regression model was ﬁtted to the outlet temperature data, which
resulted in a good model ﬁt (Fig. 7A). The obtained regression
coefﬁcient plot showed that the outlet temperature was most
affected by the inlet temperature (Fig. 7B). In addition, the
relationship between inlet air temperature and feed ﬂow rate is
depicted in response contour plot for outlet temperature (Fig. 7C).
It was observed that on increasing the feed ﬂow rate and
decreasing inlet air temperature (keeping other factors constant)
resulted in decrease of the outlet temperature.
3.3. Antigen recovery and stability after spray drying
Next to the physical powder characteristics, the antigen
characteristics were determined after spray drying. First, the
particle size of WIV was determined for each spray dried
formulation. Dynamic light scattering was performed on recon-
stituted vaccine powders. All samples dissolved readily and gave
clear opalescent liquid, which did not contain any visible
aggregates. The particle size of WIV remained unchanged for all
formulations, with an average size of 175 nm and polydispersityindexes below 0.08 (Supplementary Table 1), indicating that the
WIV particles were intact and not aggregated during or after spray
drying or reconstitution.
To assess the antigenicity of the WIV antigens after spray
drying, a hemagglutination assay was performed on the recon-
stituted vaccine powders directly after spray drying. Overall, loss of
antigenicity was minimal after spray drying, with antigenic
recoveries ranging from 86% to 100% (after 2log transformation)
(Table 3). Due to these minimal changes in antigenicity, no MLR
model could be ﬁtted on the antigenic recovery data.
In addition to the recovery of the antigen immediately after
spray drying, an accelerated stability study was performed on the
vaccine powders. Liquid WIV vaccine stored under refrigerated
conditions was taken as a control group. The powder vaccine
samples from the experimental design were sealed under a
nitrogen environment (100 mg per vial) and stored at 60 C for 3
months. The change in hemagglutinin titers upon storage was
assessed by hemagglutination assay after reconstitution of the
powder vaccines. Minimal or no loss in antigenicity was observed
after storage for 3 months at 60 C for all spray dried samples
(Table 3). In contrast, liquid WIV vaccine lost all its hemagglutinin
binding capacity after 5 days of storage at 60 C. This indicates that
spray dried WIV powder vaccines are much more resistant to heat
stress than conventional liquid vaccines.
3.4. Prediction power of the DoE model
An advantage of the generated MLR models is that they can be
used to predict process or product parameters (in this case outlet
temperature, powder particle size, powder yield, and RMC) for
combinations of the different input process parameters that have
not been tested yet. As previously described, the study obtained
valid models for outlet temperature, particle size, powder yield
and moisture content. The structured approach helped in
identifying a design space where the established QTPP can be
achieved (Fig. 9). The prediction ability of the model was tested by
selecting input parameters that would result in predeﬁned product
speciﬁcations for three untested formulations. The calculation for
prediction are based on statistical values from the model
calculated by MODDE software (Lundstedta et al., 1998). Experi-
ment A was selected in the sweet spot region, which would result
in a product according to the deﬁned QTPP. Experiments B and C
were selected outside the sweet spot, which would yield powder
vaccines that would not meet all the QTTP criteria (Table 4). Using
the selected target product characteristics as input, the acquired
Fig. 4. Regression model for yield. A: Summary of ﬁt plot for powder yield. R2 (Goodness of ﬁt = 0.825). Q2 (Goodness of prediction = 0.688). B: Regression coefﬁcients of
powder yield after model reﬁnement. Aspirator was set at maximum capacity. C. Response contour plots for powder yield. The effect of the two most inﬂuential factors (as
observed from B) was taken into account and other factors were kept constant. The color regions represent the predicted response (powder yield) for deﬁned parameter
settings. Aspirator was set at maximum instrument setting.
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desired product (Table 4). For experiment A, the experimentally
acquired data indeed correlated in range with the predicted values
for particle size (predicted 3.38 mm, observed 3.08 mm), RMC
(predicted 2.1%, observed 2.4%), powder yield (predicted 80.2%,
observed 77%) and outlet temperature (predicted 67.1 C, observed
67 C) (Table 5). The predicted parameters thus yielded a powder
vaccine that met all the criteria of the QTTP. The output parameters
(particle size, powder yield and outlet temperature) of experi-
ments B and C also concurred with the responses predicted by the
model, with the exception of the RMC for experiment C, which was
lower (2.8%) than the predicted (3.6%) RMC. These data indicate
that the predictions made by the model were accurate.
4. Discussion
The present study demonstrates the usefulness of a DoE
approach to understand the effects of spray drying process
parameters and excipient concentration on the production ofstable spray dried inﬂuenza vaccines. The main ﬁndings are
summarized in Table 6.
4.1. Effect of nozzle pressure (atomization gas ﬂow rate)
In general, the nozzle pressure (7.3–17.5 L/min) was the most
inﬂuential process parameters for the studied characteristics of the
obtained powder vaccine. An increase in gas (nitrogen) pressure on
the nozzle resulted in decreased particle size, which can be related
to the increased energy available for breaking up the liquid jet by
the nozzle, thus forming smaller particles during atomization. This
was in line with previous studies from Maltesen et al. (Maltesen
et al., 2008), who reported a decrease in particle size of spray dried
product from 26 mm to 9.8 mm when increasing the nozzle
pressure in the range from 7.3 to 17.5 L/min. In addition, the
interaction factor (Noz*Noz) (Fig. 3B) showed an opposite effect
compared to the main factor nozzle pressure, indicating that the
relationship between nozzle pressure and particle size could be
non-linear outside the studied range.
Fig. 5. Regression model for residual moisture content. A: Summary of ﬁt plot for residual moisture content. R2 (Goodness of ﬁt = 0.976). Q2 (Goodness of prediction = 0.860).
B: Regression coefﬁcients of residual moisture content after model reﬁnement. Aspirator was set at maximum capacity. C. Response contour plots for residual moisture
content. The effect of the two most inﬂuential factors (as observed from Fig B) were taken into account and other factors were kept constant. The color regions represent the
predicted response (RMC) for deﬁned parameter settings. Aspirator was set at maximum instrument setting.
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decrease in nozzle pressure decreases the imparted kinetic energy
of the gas on the dispersed liquid, resulting in bigger droplets with
smaller surface area for drying, that increases deposition in the
drying chamber and hence decreases the yield. This deposit was
visually observed on the inside wall of the drying chamber which
increased with decreasing nozzle pressure. These results are
consistent with research by Maury et al. (2005), which observed a
trend of decreasing powder yield (from 60% to 40%) with
decreasing the nozzle pressure from 13.4 L/min to 8.3 L/min at a
ﬁxed inlet temperature of 170 C. Furthermore, the model for
residual moisture content shows an increase in RMC of the powder
with decreasing nozzle pressure. This result is likely to be related to
the formation of larger particles at decreasing nozzle pressure,
which leads to a reduced speciﬁc surface area for evaporation.
Although not being the most inﬂuencing parameter (in contrast
to the inlet air temperature), the nozzle pressure appears to reduce
the outlet temperature. This relation is consistent with the data
obtained by Maa et al. (1997), who observed a similar relation with
nozzle pressure, while spray drying a IgE class monoclonal
antibody with trehalose.4.2. Effect of inlet air temperature
The inlet air temperature for the drying was varied between
110 C and 160 C and had a signiﬁcant effect on vaccine powder
characteristics. It was observed that the outlet air temperature
increases linearly with the increase in inlet air temperature.
Moreover, this correlation is consistent with observations by
Maltesen et al. (2008) who reported linear increase in outlet
temperatures while varying the inlet temperature between 75 C
and 220 C. In the current study, the maximum outlet temperature
observed was 91 C. This is below the theoretical glass transition
temperature of trehalose (117 C) (Hinrichs et al., 2001). Further-
more, water is known to be a potent plasticizer for sugar glasses
(Hinrichs et al., 2001), which reduces the Tg values and could lead
to crystallization of sugar during storage. However, the amorphous
nature of the powder vaccine was conﬁrmed by X-ray diffraction
(discussed later).
Besides that, an increase of inlet temperature decreases the
RMC of the powder. This observation could be attributed to the
increased energy available for water evaporation during the drying
process. As expected, the model shows that a higher inlet
temperature would lead to better drying.
Fig. 6. X-ray diffraction (XRD). The patterns of spray dried vaccine samples in comparison with trehalose dihydrate (red). Vaccine product: black (run1), green (run5), brown
(run 10), blue (run11), pink (run22). Trehalose dihydrate, the starting material is crystalline as depicted by the sharp peaks in the ﬁgure (red). In contrary, the spray-dried
vaccine powder was amorphous with no sharp peaks. The formulations for XRD evaluation were selected based on their residual moisture content and anticipated potential of
trehalose to crystallize in the product (predicted Tg vs T outlet). Run 1 and run 5 had RMC in higher range (4–7%) and run10, 11 and 22 had RMC in lower ranges (2–3%).
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Increasing the feed ﬂow rate avails more ﬂuid for dispersion per
unit of energy available for atomization. This results in insufﬁcient
water evaporation and thus higher moisture content. This was
observed in our study (experiment 5). Furthermore, increased
water available for evaporation leads to a decrease in outlet
temperature (Table 6).
In addition, increasing the feed ﬂow rate decreases the powder
yield in this model to 42% at highest feed ﬂow rate. However, a
decrease in yield with high feed ﬂow rate can be compensated with
increasing nozzle pressure as observed in experiment 6 (powder
yield: 72%). Thus, it could be inferred that nozzle pressure in
combination with feed ﬂow rate is signiﬁcantly inﬂuencing the
powder yield.
4.4. Effect of excipient concentration
In the current investigated parameter combinations, the
excipient concentration alone did not play a signiﬁcant role on
the product characteristic. However, the excipient concentration
signiﬁcantly inﬂuenced the product characteristics when also
other process parameter were changed. Trehalose was used in the
concentration range of 50 mg/mL–150 mg/mL. In general, increas-
ing the trehalose concentration increases density and decreases
porosity of the particles. Furthermore, increasing trehalose
concentration may lead to more deposition in the drying chamber
and thereby a reduced powder yield (Adler and Lee, 1999). In
addition, the concentration and solubility of excipients affects the
particle morphology. The precipitation kinetics and possiblecrystallization (although not the case in our study) could play
an important role and are affected by the rate of evaporation of
water during drying (Vehring, 2008; Vehring, 2007).
4.5. Amorphousness of the powder
Spray drying of trehalose resulted in an amorphous powder as
observed in several previous studies (Baldinger et al., 2012; Zhu
et al., 2014). For several sugars the amorphous glassy state may
reduce the molecular mobility to the included compounds such as
vaccine antigens (Tonnis et al., 2015). The limited mobility reduces
protein aggregation/unfolding and chemical degradation reac-
tions.
Although the reported glass transition temperature of fully
amorphous trehalose is 117 C, we observed Tg values as low as
43 C for the formulation with highest moisture content. This
reduced Tg is explained by the fact that water is a potent plasticizer
for sugar glasses (Hinrichs et al., 2001). However, with the current
understanding of the drying process, the RMC can be decreased to
an acceptable level (<3%). Moreover, the spray dried vaccine
formulations with high RMC stayed amorphous as conﬁrmed by
powder XRD. However, it cannot be excluded that during storage
for longer time, trehalose might crystallize to some extent.
4.6. Antigenicity and antigen stability
The antigen recovery of inﬂuenza vaccine after spray drying was
above 86% for all experiments in the investigated design space. Due
to limited variation in antigenicity between the different
formulations during drying no regression model could be ﬁtted
Fig. 7. Regression model of outlet temperature. A: Summary of ﬁt plot for residual outlet temperatures. R2 (Goodness of ﬁt = 0.968). Q2 (Goodness of prediction = 0.926). B:
Regression coefﬁcients of outlet temperatures after model reﬁnement. C. Response contour plots for outlet temperature. The effect of the two most inﬂuential factors (as
observed from Fig B) was taken into account and other factors were kept constant. The color regions represent the predicted response (outlet temperature) for deﬁned
parameter settings. Aspirator was set at maximum instrument setting.
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parameters on antigenic recovery could not be assessed. Trehalose
was a suitable excipient to stabilize inﬂuenza vaccine during and
after the spray drying process. The powder formulations remained
stable for 3 months of storage at 60 C, on the other hand liquid
WIV stored at 60 C completely lost its activity within 5 days of
storage. While this is the ﬁrst report on the stability of spray dried
WIV vaccine, other studies have shown that spray dried inﬂuenza
subunit antigens remain stable at elevated temperatures when
trehalose was used as the main excipient. Zhu et al. (2014)
observed trehalose containing inﬂuenza vaccine formulation
protected the antigen during storage at 50 C for 2 months.
Furthermore, Sou et al. (2015) showed that trehalose and leucine
containing inﬂuenza vaccine formulations had stable HA titers
after being stored at 40 C for 2 months. Other drying methods
such as freeze-drying (Soema et al., 2014), spray freeze drying
(Lundstedta et al., 1998) and foam drying (Maury et al., 2005) have
also yielded stable dried inﬂuenza vaccines. Besides this, the
potential of spray dried inﬂuenza vaccines for pulmonary
administration has been demonstrated by several previous
preclinical studies (Saluja et al., 2010; Scherliess et al., 2014;
Sou et al., 2015).4.7. Prediction of spray-drying process parameter combinations for a
speciﬁc Quality Target Product Proﬁle
The acquired model predicted particle size, outlet temperature,
moisture content and powder yield accurately for the dried vaccine
within the obtained design space. Formulation A, chosen from the
sweet spot (Inlet temperature 120 C, Nozzle gas ﬂow rate 12.4 L/
min, feed ﬂow rate of 1.0 mL/min and trehalose concentration of
100 mg/mL) resulted in a product with the desired quality product
proﬁle (QTPP). Even with varying the settings of nozzle gas ﬂow
rate (experiment B and C to 10.5 and 9.0 L/min respectively)
outside the sweet spot region but within the predicted design
space resulted in a product within the deﬁned target product
proﬁle. The only exception observed was for experiment C, where
the RMC varied from the predicted value. It could be the case, that
handling of powder during collection and analysis contributed to
this variation. Although, the residual moisture content of all the
produced powders was less than 3%, which is the upper-limit for
dried biologicals in European Pharmacopoeia (May et al., 1992).
This indicates towards a well-deﬁned design space and good
prediction abilities of the obtained model. One can presume that
any other experiments performed within the experimental
Fig. 8. Predicted values for outlet temperatures by two different models. The values
predicted from our model in comparison with values predicted from the model by
Grasmeijer et al. (Grasmeijer, 2013).
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product characteristics. Furthermore, the WIV vaccine antigenicity
remained unaffected during drying and subsequent reconstitution
within the current design. The stability of WIV outside the current
spray drying design space cannot be predicted and might be
different outside the design space. At this stage, we cannot model
the antigenicity of the vaccine because of limited variation in
antigenicity between the different formulations; a further expan-
sion of the design space to more extreme spray drying conditions
may induce differences in antigenicity. However, it is debatable if
such extreme conditions would ever be used in an actual
production setting. Furthermore, a good correlation was found
between the outlet temperature predicted by a mathematical
model from Grasmeijer et al. and the outlet temperature predicted
by model described in the current study (Fig. 8, R2 = 0.91)
(Grasmeijer, 2013). This combination of ﬁndings provides some
conceptual premise that could be applied for regulating the
physical powder characteristics during spray drying for other
vaccine candidates. The biological/antigenic stability theseFig. 9. The predicted design space. The parameters feed ﬂow rate at 1.0 mL/min and
feed excipient concentration at 100 mg/mL were ﬁxed for the predicted design
space. The criteria were set for particle size range of 1–5 mm, the outlet temperature
below 100 C, residual moisture content between 1 and 3% and the process yield
above 70%. The criteria for powder vaccine were set in accordance with QTTP. Color
code: Red (one criteria met), orange (two criteria met), yellow (three criteria met),
green (all criteria met/sweet spot). The feed concentration and feed ﬂow rate for the
current design were predicted as 100 mg/mL and 1.0 mL/min respectively. Points A,
B and C represent the spray drying runs that were performed to conﬁrm the
prediction abilities of the model. In all experiments aspirator was set at maximum
equipment setting.candidate vaccines might vary depending on their ability to
withstand extremes of spray drying conditions. One needs to
accurately assess this by performing spray drying runs including
these individual vaccine candidates.
In conclusion, the current study successfully demonstrates the
application of QbD principles and the DoE approach in the
development of a dry powder inﬂuenza vaccine formulation. This
approach provided an overview of the impact of process
parameters that affect the spray dried vaccine product character-
istics as summarized in Table 6. The approach gave a descriptive
model of a design space in which trehalose based WIV vaccine
powder with a product proﬁle of particle size 1–5 mm, powder
yield above 70% and residual moisture content below 3% were
produced using Büchi mini spray-drier B-290. The produced spray
dried inﬂuenza vaccine contained WIV that retained its antigenic-
ity, and was thermostable for several months upon storage at 60 C.
Finally, the descriptive model was suitable to deﬁne and
subsequently select process settings to produce a vaccine powder
with predeﬁned characteristics, as conﬁrmed by experiments.
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